Lyra Therapeutics (LYRA) Misses Q2 EPS by 534c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts LYRA Hot Sheet
Join SI Premium – FREE
Lyra Therapeutics (NASDAQ: LYRA) reported Q2 EPS of ($5.51), $5.34 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $183 thousand versus the consensus estimate of $242 thousand.
For earnings history and earnings-related data on Lyra Therapeutics (LYRA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- ADP Employment Change (Oct) 86K vs 67K Expected
- Fidelity National Information Services, Inc. (FIS) Tops Q3 EPS by 1c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
